Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

334.58
-3.9900-1.18%
Post-market: 334.50-0.0800-0.02%19:54 EDT
Volume:175.39K
Turnover:59.39M
Market Cap:9.32B
PE:-26.01
High:348.00
Open:340.00
Low:334.00
Close:338.57
52wk High:392.70
52wk Low:37.25
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.71
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.95
PE(LYR):-24.83

Loading ...

Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline and De-Risked Ulixacaltamide NDA Support Unchanged $554 Buy Target

TIPRANKS
·
May 08

Praxis Precision Medicines publishes corporate presentation on CNS pipeline, near-term regulatory catalysts

Reuters
·
May 07

Praxis Precision's Q1 net loss widens on higher expenses

Reuters
·
May 07

Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate

Benzinga Earnings
·
May 07

BRIEF-Praxis Precision Q1 EPS USD -3.2

Reuters
·
May 07

Praxis Precision Q1 Operating Income USD -105.86 Million

THOMSON REUTERS
·
May 07

Praxis Precision Q1 Net Income USD -92.561 Million

THOMSON REUTERS
·
May 07

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07

Praxis Precision Medicines grants 5,420 RSUs to 21 new employees under inducement plan

Reuters
·
May 06

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06

Praxis Precision Medicines Inc expected to post a loss of $3.57 a share - Earnings Preview

Reuters
·
May 05

Praxis Precision Medicines updates financial calendar for first-quarter results and investor conference

Reuters
·
May 05

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

GlobeNewswire
·
May 05

How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates

Simply Wall St.
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)

TIPRANKS
·
Apr 26

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Apr 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)

TIPRANKS
·
Apr 24

Praxis Precision Medicines (PRAX) Gets a Buy from LifeSci Capital

TIPRANKS
·
Apr 22

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE)

TIPRANKS
·
Apr 18

Praxis Ulixacaltamide Milestone Reframes Essential Tremor Opportunity And Valuation

Simply Wall St.
·
Apr 18